Ibrutinib acalabrutinib in fixed-duration chronic lymphocytic leukemia therapy: a comparative analysis of efficacy.
APA
Molica S, Shanafelt TD, et al. (2026). Ibrutinib acalabrutinib in fixed-duration chronic lymphocytic leukemia therapy: a comparative analysis of efficacy.. Haematologica, 111(1), 412-417. https://doi.org/10.3324/haematol.2025.288323
MLA
Molica S, et al.. "Ibrutinib acalabrutinib in fixed-duration chronic lymphocytic leukemia therapy: a comparative analysis of efficacy.." Haematologica, vol. 111, no. 1, 2026, pp. 412-417.
PMID
40605690
같은 제1저자의 인용 많은 논문 (5)
- CLL17: Fixed-duration paradigms match continuous ibrutinib in frontline chronic lymphocytic leukemia.
- Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.
- Fixed-duration BTKi-venetoclax combinations in CLL: optimizing patient-centered care.
- Beyond progression-free survival (PFS): time to next treatment (TTNT) as a patient-centered metric of clinical benefit in chronic lymphocytic leukemia (CLL).
- Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.